Skip to main content

Table 4 Comparisons of treatment

From: Clinical features and risk factors analysis of bronchitis obliterans due to refractory Mycoplasma pneumoniae pneumonia in children: a nomogram prediction model

Factors

BO

(n = 65)

Non-BO

(n = 76)

Z/χ2

p

Timing of macrolides < 5 days of disease course (n %)

25 (38.5%)

60 (78.9%)

22.985

 < 0.001

Total course of macrolides (days)

12.0 (8.0,15.0)

10.0 (8.0,12.0)

 − 2.186

0.029

Course of Azithromycin (days)

8.0 (8.0,10.0)

8.0 (8.0,8.0)

 − 0.284

0.776

Course of Erythromycin (days)

3.0 (0.0,7.0)

1.5 (0.0,4.0)

 − 2.171

0.030

Glucocorticoid

58 (89.2%)

65 (85.5%)

0.432

0.511

Timing of glucocorticoid < 2 weeks (n %)

29 (44.6%)

62 (81.6%)

20.916

 < 0.001

Course of Glucocorticoid

5.0 (3.0,8.0)

2 (3.0,8.0)

1.907

0.057

Fiberoptic bronchoscopy (n %)

65 (100%)

62 (81.6%)

13.294

 < 0.001

Treatment timing of fiberoptic bronchoscopy < 2 weeks (n %)

16 (24.6%)

51 (67.1%)

25.364

 < 0.001

First treatment time of fiberoptic bronchoscopy (days)

17.0 (14.0,23.0)

12 (10.0,13.0)

 − 6.379

 < 0.001

Twice bronchoscopy

25 (38.5%)

2 (2.6%)

26.783

 < 0.001

Phlegm plug (n %)

36 (55.4%)

29 (38.2%)

4.184

0.041

Mucosal necrosis (n %)

13 (20.0%)

7 (9.2%)

3.351

0.067

Plastic bronchitis (n %)

17 (26.2%)

6 (7.9%)

8.556

0.003

  1. *p represents the p value calculated by Fisher’s exact probability method